Callos Andrew 4

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), disposed of 8,542 shares on 2026-03-17 in two sell transactions at $62.15 per share. The trades were for 5,626 shares ($349,656) and 2,916 shares ($181,229), totaling roughly $530,885. These were sales (not purchases) and were reported as company-compelled sell-to-cover transactions to satisfy tax withholding obligations tied to RSU vesting.

Key Details

• Transaction date: 2026-03-17; Price per share: $62.15.
• Shares sold: 5,626 and 2,916 (total 8,542); Total proceeds: ~$530,885.
• Transaction type: Sale (reported as open market or private sale) with footnotes indicating company-compelled sell-to-cover for RSU tax withholding (Footnotes F1, F2).
• Shares owned after the transaction: Not specified in the provided filing details.
• Filing: Report filed 2026-03-18 for transactions on 2026-03-17 (appears timely). No 10b5-1 plan or other trading plan noted in the provided details.

Context: Sell-to-cover transactions are routine tax-withholding actions when restricted stock units vest and do not necessarily indicate an executive-initiated decision to reduce exposure. Purchases generally carry more weight as signals of insider confidence; this filing documents a tax-related disposition.